Cynosure Expands Best-In-Class Potenza™ RF Microneedling System

Cynosure announced today the U.S. launch of its one-of-a-kind Fusion Tip, the newest addition to its best-in-class Potenza™ radiofrequency (RF) microneedling system.

With its dual-air chamber design, the Fusion Tip captures and releases air towards the skin with each pulse, enhancing the penetration of topicals into the skin by 67% for maximum results.

“We’re constantly challenging ourselves to drive innovation forward and deliver differentiated technologies that allow our customers to provide better, more customizable treatments for their patients,” said Todd Tillemans, Chief Executive Officer of Cynosure. “The Fusion Tip is the first and only RF microneedling tip on the market designed to enhance the penetration of topicals deeper into the dermis, improving the quality of your skin. This is a real game changer for RF microneedling and we’re proud to be at the forefront of this next-level technology.”

The Fusion Tip is the latest addition to Cynosure’s Potenza system, the world’s first 4-mode RF microneedling device, which uses ultrafine needles and radiofrequency energy to penetrate the top layer of the skin, triggering the body’s natural healing process to regenerate new collagen and elastin. Unlike other treatments on the market, Potenza treatments can be performed on all skin types, anywhere on the body and any time of year. Now with the single-use, disposable Fusion Tip, practitioners can maximize topical penetration while tightening the skin through soft tissue coagulation, revolutionizing the standard microneedling treatment.

“Potenza’s new Fusion Tip enables me to confidently deliver topicals deeper in the dermis, allowing me to reach where it matters most,” said Dr. Deanne Mraz Robinson of Modern Dermatology in Westport, CT. “By enhancing the penetration of topicals into the skin, I am able to maximize patient results.”

Of the Potenza system’s four modes (monopolar or bipolar, delivered at either 1 MHz or 2 MHz frequency), the Fusion Tip operates in monopolar at 1 MHz for deep and wide RF delivery and enhanced tissue engagement and topical penetration. While three to five treatments at roughly four to six weeks apart are recommended, patients may notice improvements in their skin after the first or second treatment and will continue to see improvements six to 12 months post-treatment.

The Fusion Tip is commercially available in the U.S. and only compatible with Cynosure’s Potenza device.

SourceCynosure

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”